卡瑞利珠单抗致药品不良反应的文献病例分析

Literature Case Analysis of Adverse Drug Reactions Induced by Camrelizumab

目的:探讨卡瑞利珠单抗所致药品不良反应(ADR)的类型和临床特点,为临床安全用药提供参考。方法:检索国内主要中文文献数据库,收集2019年6月~2022年4月卡瑞利珠单抗所致ADR病例报道文献,统计分析病例的年龄性别、原患疾病、联合用药,以及ADR发生时间、临床表现、分级和治疗转归等情况。结果:检索到卡瑞利珠单抗ADR病例报道的相关文献32篇,共35例病例,其中男24例,女11例,年龄35~76(58.62±10.18)岁;原患疾病以肺癌居多(14例,40.0%);联合用药病例19例(54.3%),联用最多的药物是紫杉醇;ADR诱导期≤30 d有19例(54.3%),>30 d有16例(45.7%);ADR发生在免疫治疗第1周期有14例(31.4%);ADR主要累及皮肤及其附件(16例,41.0%)、循环系统(7例,17.9%)和呼吸系统(5例,12.8%)。结论:临床医生在应用卡瑞利珠单抗时应准确把握用药指征,严格按照说明书,熟悉其ADR常见类型和发生时间,加强ADR监测,确保患者用药安全。

Objective: To research the ADR types and clinical characteristics of camrelizumab, so as to provide reference for clinical medication. Methods: The main Chinese literature databases in China were searched, and the ADR case reports of camrelizumab from June 2019 to April 2022 were collected. Age and sex, original diseases, combined medication, ADR occurrence time, clinical manifestation, ADR classification and treatment outcomes were statistically analyzed for the cases. Results: Totally 35 cases from 32 papers were collected. Among the patients, there were 24 males and 11 females, whose age ranged from 35 to 76 years with the average age of(58.62±10.18) years. The original disease mostly performed as lung cancer(14 cases, 40.0%);19 cases were performed combined medication, among which the most commonly used regimen was the combined administration of paclitaxel. ADR induction period was ≤30 d in 19 cases(54.29%), while that was >30 d in 16 cases(45.71%). During the periods of immunotherapy, ADR occurred in the first period in 14 cases(31.43%);the ADR mainly involved skin and its accessories(16 cases, 41.03%), circulatory system(7 cases, 17.95%) and respiratory system(5 cases, 12.81%). Conclusion: Clinicians should grasp the medication indications, strictly follow the instruction, be familiar with the common types of ADRs and their occurrence time, strengthen the monitoring of ADRs, and ensure the safety of drug use.